Frontotemporal Dementia, Where Do We Stand? A Narrative Review

被引:35
|
作者
Antonioni, Annibale [1 ,2 ]
Raho, Emanuela Maria [1 ]
Lopriore, Piervito [3 ]
Pace, Antonia Pia [4 ]
Latino, Raffaela Rita [5 ]
Assogna, Martina [6 ,7 ]
Mancuso, Michelangelo [3 ]
Gragnaniello, Daniela [8 ]
Granieri, Enrico [1 ]
Pugliatti, Maura [1 ]
Di Lorenzo, Francesco [7 ]
Koch, Giacomo [7 ,9 ,10 ]
机构
[1] Univ Ferrara, Neurosci & Rehabil Dept, Unit Clin Neurol, I-44121 Ferrara, Italy
[2] Univ Ferrara, Doctoral Program Translat Neurosci & Neurotechnol, I-44121 Ferrara, Italy
[3] Univ Pisa, Neurol Inst, Dept Clin & Expt Med, I-56126 Pisa, Italy
[4] Univ Udine, Univ Hosp S Maria Misericordia, Azienda Sanit Universitaria Friuli Cent, Inst Radiol,Dept Med, I-33100 Udine, Italy
[5] Fdn Ist Ricovero & Cura Carattere Sci Casa Solliev, Emergency Dept, Complex Struct Neurol, I-71013 San Giovanni Rotondo, Italy
[6] Univ Roma Tor Vergata, Ctr Demenze, Policlin Tor Vergata, I-00133 Rome, Italy
[7] Ist Ricovero & Cura Carattere Sci Santa Lucia, Non Invas Brain Stimulat Unit, I-00179 Rome, Italy
[8] Ferrara Univ Hosp, Neurosci & Rehabil Dept, Nuerol Unit, I-44124 Ferrara, Italy
[9] Ist Italiano Tecnol, IitUnife Ctr Translat Neurophysiol, I-44121 Ferrara, Italy
[10] Univ Ferrara, Neurosci & Rehabil Dept, Sect Human Physiol, I-44121 Ferrara, Italy
关键词
frontotemporal dementia (FTD); primary progressive aphasias; behavioural variant; neurodegenerative dementias; biomarkers; non-Alzheimer's disease dementias; tau; C9orf72; AMYOTROPHIC-LATERAL-SCLEROSIS; PRIMARY PROGRESSIVE APHASIA; TRANSCRANIAL MAGNETIC STIMULATION; HEXANUCLEOTIDE REPEAT EXPANSION; CEREBROSPINAL-FLUID LEVELS; NEUROFILAMENT LIGHT-CHAIN; FRONTAL-LOBE DEGENERATION; RIGHT TEMPORAL VARIANT; BEHAVIORAL-VARIANT; ALZHEIMERS-DISEASE;
D O I
10.3390/ijms241411732
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Frontotemporal dementia (FTD) is a neurodegenerative disease of growing interest, since it accounts for up to 10% of middle-age-onset dementias and entails a social, economic, and emotional burden for the patients and caregivers. It is characterised by a (at least initially) selective degeneration of the frontal and/or temporal lobe, generally leading to behavioural alterations, speech disorders, and psychiatric symptoms. Despite the recent advances, given its extreme heterogeneity, an overview that can bring together all the data currently available is still lacking. Here, we aim to provide a state of the art on the pathogenesis of this disease, starting with established findings and integrating them with more recent ones. In particular, advances in the genetics field will be examined, assessing them in relation to both the clinical manifestations and histopathological findings, as well as considering the link with other diseases, such as amyotrophic lateral sclerosis (ALS). Furthermore, the current diagnostic criteria will be explored, including neuroimaging methods, nuclear medicine investigations, and biomarkers on biological fluids. Of note, the promising information provided by neurophysiological investigations, i.e., electroencephalography and non-invasive brain stimulation techniques, concerning the alterations in brain networks and neurotransmitter systems will be reviewed. Finally, current and experimental therapies will be considered.
引用
收藏
页数:34
相关论文
共 50 条
  • [31] Delirium: Where do we stand?
    Pae C.-U.
    Marks D.M.
    Han C.
    Patkar A.A.
    Masand P.
    Current Psychiatry Reports, 2008, 10 (3) : 240 - 248
  • [32] Hyperfractionation: Where do we stand?
    BeckBornholdt, HP
    Dubben, HH
    LiertzPetersen, C
    Willers, H
    RADIOTHERAPY AND ONCOLOGY, 1997, 43 (01) : 1 - 21
  • [33] Tuberculosis: Where do we stand?
    Becx-Bleumink, M
    Broekmans, JF
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 1998, 3 (06) : 423 - 424
  • [34] WHERE DO WE STAND ON METRIFICATION
    KIRCHER, KF
    DESIGN NEWS, 1969, 24 (02) : 1 - &
  • [35] Reflections on "Where Do We Stand?"
    Weber, Jennifer L.
    CIVIL WAR HISTORY, 2014, 60 (04) : 404 - 406
  • [36] Biomarkers, Where Do We Stand
    Dixit, Vikash
    Sharma, Payal
    Dhage, Atul Dyandeo
    INDIAN JOURNAL OF PSYCHIATRY, 2015, 57 (05) : S165 - S166
  • [37] Pegasparaginase: where do we stand?
    Zeidan, Amer
    Wang, Eunice S.
    Wetzler, Meir
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (01) : 111 - 119
  • [38] Pharmacovigilance: Where do we stand?
    Peethambaran, K.
    Khanwelkar, C. C.
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2010, 4 (03) : 2636 - 2637
  • [39] TUBERCULOSIS - WHERE DO WE STAND
    HOLGUIN, AH
    JOURNAL OF THE AMERICAN COLLEGE OF HEALTH ASSOCIATION, 1968, 17 (02): : 175 - 178
  • [40] QCD - WHERE DO WE STAND
    ALTARELLI, G
    MULTIPARTICLE DYNAMICS 1988, 1988, : 253 - 253